BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 29, 2025
See today's BioWorld
Home
» Better together? Investors lukewarm as Shire backs Takeda's $62B offer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Better together? Investors lukewarm as Shire backs Takeda's $62B offer
May 9, 2018
By
Cormac Sheridan
No Comments
DUBLIN – Takeda Pharmaceutical Co. Ltd. has convinced the board of Shire plc of the merits of its £46 billion (US$62.1 billion) cash-and-shares takeover offer. Now it must do likewise with Shire's investors – as well as its own.
BioWorld